Contact UsInvestorsCareersMediaScienceContact Us
HomeProductsPrescription MedicinesTicoVac

This page is intended as reference information for the general public in Great Britain.

Ticovac® (tick-borne encephalitis virus adsorbed)

What is TicoVac and what is it used for?

TicoVac 0.5 ml is a vaccine for the active (prophylactic) immunisation of people aged 16 years or older against tick-borne encephalitis (TBE). TicoVac Junior 0.25 ml is indicated for children aged between 1 and 15 years of age.

TicoVac help protects against TBE virus, a member of the flavivirus family that can affect the central nervous system. TBE virus is transmitted to humans by the bite of an infected tick and is almost exclusively restricted to areas of Europe and Asia. 

How Does the Vaccine Work?

TicoVac contains the Tick-Borne Encephalitis Virus which is inactivated using formaldehyde and itself cannot cause disease. The individual's immune system is stimulated by the inactivated virus, producing antibodies against it which in turn provides them with protection against TBE.

When Should the Vaccine Be Administered?

TicoVac 0.5 ml and TicoVac Junior 0.25 ml is to be given on the basis of official recommendations regarding the need for, and timing of, vaccination against TBE.

As with all vaccines, TicoVac and TicoVac Junior may not protect everyone who is fully vaccinated. 

The medicine can only be obtained with a prescription.

Reference Information

If you would like to see the Patient Information Leaflet or Summary of Product Characteristics for TicoVac or TicoVac Junior these can be found at the electronic Medicines Compendium (eMC).

If you would like to see the latest information on vaccines and vaccination procedures for TicoVac and TicoVac Junior in the UK, please visit The Green Book

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.

PP-TCV-GBR-0150 / February 2023
Science Products Responsibility PartnershipsCareers Privacy Statement Terms of Use Contact UsSitemap Copyright © 2017-2024 Pfizer Limited. PP-UNP-GBR-8108 / January 2024. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427. This website is intended for the general public in the UK.